MedTrace Logo

Shared Decision Making for Choosing Autosomal DOminant Polycystic Kidney Disease Treatment

NCT06618638 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 340

Last updated 2024-11-07

No results posted yet for this study

Summary

The purpose of this study is to generate clinical evidence and assess the feasibility of a shared decision-making (SDM) model for the selection of Tolvaptan in patients with ADPKD.

Conditions

  • ADPKD (autosomal Dominant Polycystic Kidney Disease)

Interventions

BEHAVIORAL

Shared decision making model

Shared decision making model for choosing pharmacotherapy in ADPKD patients. This newly developed shared decision making model follows the SHARE approach and includes patient education, identifying values and preferences, reaching a decision and evaluating.

BEHAVIORAL

Usual Care

Usual care for ADPKD patients

Sponsors & Collaborators

  • Seoul National University

    collaborator OTHER

  • Hallym University Kangnam Sacred Heart Hospital

    collaborator OTHER

  • Kangbuk Samsung Hospital

    collaborator OTHER

  • Korea University Guro Hospital

    collaborator OTHER

  • Seoul National University Boramae Hospital

    collaborator OTHER

  • Asan Medical Center

    collaborator OTHER

  • InjeUniversityBusanPaikHospital

    collaborator UNKNOWN

  • Chonnam National University Hospital

    collaborator OTHER

  • Keimyung University Dongsan Medical Center

    collaborator OTHER

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Yong Chul Kim · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-21
Primary Completion
2026-09-30
Completion
2026-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06618638 on ClinicalTrials.gov